<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793465</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00145800</org_study_id>
    <nct_id>NCT03793465</nct_id>
  </id_info>
  <brief_title>Pilot-Tart Cherry, Mitral Transcriptome, and POAF Incidence</brief_title>
  <official_title>Pilot-Tart Cherry, Mitral Transcriptome and POAF Incidence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cherry Marketing Institute, Dewitt MI (USA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess impact of Tart Cherry Concentrate in cardiac surgical patients on POAF and related
      clinical and economic outcomes. Measure inflammation gene transcripts in cardiac tissue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Consumption - 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported tolerability score</measure>
    <time_frame>One week</time_frame>
    <description>Patients will complete a brief questionnaire regarding gastrointestinal status, using the Bristol Stool Form Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as measured by total number of days in hospital within 60 days of surgery</measure>
    <time_frame>60 days</time_frame>
    <description>Total number of days in hospital within 60 days of the index surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to conversion to normal sinus rhythm</measure>
    <time_frame>30 days</time_frame>
    <description>Perioperative time to conversion to normal sinus rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rhythm at hospital discharge</measure>
    <time_frame>30 days</time_frame>
    <description>Heart rhythm at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rhythm at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Heart rhythm at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for permanent pacemaker within 30 days of surgery</measure>
    <time_frame>30 days</time_frame>
    <description>Need for permanent pacemaker within 30 days of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular thromboembolism [stroke, TIA]</measure>
    <time_frame>30 days</time_frame>
    <description>Incidences (yes/no, total number) of Cerebrovascular thromboembolism [stroke, TIA]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cerebrovascular thromboembolism</measure>
    <time_frame>30 days</time_frame>
    <description>Incidences (yes/no, total number) of Non-cerebrovascular thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Incidences (yes/no, total number) of Bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidences (yes/no, total number) of Cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of postoperative clinical events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidences (yes/no, total number) of Non-cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>60 days</time_frame>
    <description>LOS [Index hospitalization]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Re-hospitalization and ED visits</measure>
    <time_frame>60 days</time_frame>
    <description>Number of Re-hospitalization and ED visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Outpatient Interventions</measure>
    <time_frame>60 days</time_frame>
    <description>Number of Outpatient interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Costs for Hospital stay</measure>
    <time_frame>60 days</time_frame>
    <description>Costs [incident hospital stay]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Post-operative Atrial Fibrillation (POAF)</condition>
  <arm_group>
    <arm_group_label>Tart Cherry Concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Servings (1 ounce or 2 tablespoon/serving) per day for three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>tart cherry concentrate</intervention_name>
    <description>Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery</description>
    <arm_group_label>Tart Cherry Concentrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and female patients (age 50-79) at the Mitral Valve Clinic/CVC undergoing
             elective cardiac surgery for mitral valve repair without the Cox MAZE procedure (MVR
             patients also undergoing CABG and/or tricuspid valve repair are also eligible)

          2. In sinus rhythm (no pre-operative atrial fibrillation, no hx of AF)

        Exclusion Criteria:

          1. Age â‰¥ 80 years

          2. Diagnosed pre-operative chronic or paroxysmal AF

          3. Prior ablation procedure for AF

          4. Previous cardiac surgery

          5. Implanted pacemaker

          6. Active smoker

          7. Comorbidities such as congenital or cardiac re-operation

          8. Use of antiarrhythmic agents

          9. Active inflammatory or infectious disease or malignancy

         10. Diagnosed autoimmune disease

         11. Corticosteroid or other immunomodulatory or immunosuppressive medication

         12. Known sensitivity to sorbitol

         13. Known gastric sensitivity to acidic juices like orange juice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Shuler, RN</last_name>
    <phone>734-232-4297</phone>
    <email>gervais@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Shuler, RN</last_name>
      <phone>734-232-4297</phone>
      <email>gervais@med.umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Steven Bolling</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

